Zacks Investment Research on MSN12h
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by ...
Who's afraid of the EU-Mercosur Agreement?
Vilified by some, defended by others and misunderstood by many, the “Mercosur Agreement” is a passionate subject these days ...
Rare opportunities – ASX health stocks tackling unmet medical needs
Rare diseases have become an attractive target for pharmaceutical companies both in Australia and internationally with ...
PipelineReview.com23h
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
PALO ALTO, CA, USA I 11, 2025 I BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused ...